159 related articles for article (PubMed ID: 33400272)
21. A cutaneous lymphoma international prognostic index (CLIPi) for mycosis fungoides and Sezary syndrome.
Benton EC; Crichton S; Talpur R; Agar NS; Fields PA; Wedgeworth E; Mitchell TJ; Cox M; Ferreira S; Liu P; Robson A; Calonje E; Stefanato CM; Wilkins B; Scarisbrick J; Wain EM; Child F; Morris S; Duvic M; Whittaker SJ
Eur J Cancer; 2013 Sep; 49(13):2859-68. PubMed ID: 23735705
[TBL] [Abstract][Full Text] [Related]
22. Transformation of mycosis fungoides/Sezary syndrome: clinical characteristics and prognosis.
Diamandidou E; Colome-Grimmer M; Fayad L; Duvic M; Kurzrock R
Blood; 1998 Aug; 92(4):1150-9. PubMed ID: 9694702
[TBL] [Abstract][Full Text] [Related]
23. Blood classification and blood response criteria in mycosis fungoides and Sézary syndrome using flow cytometry: recommendations from the EORTC cutaneous lymphoma task force.
Scarisbrick JJ; Hodak E; Bagot M; Stranzenbach R; Stadler R; Ortiz-Romero PL; Papadavid E; Evison F; Knobler R; Quaglino P; Vermeer MH
Eur J Cancer; 2018 Apr; 93():47-56. PubMed ID: 29477101
[TBL] [Abstract][Full Text] [Related]
24. Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression.
Kim YH; Liu HL; Mraz-Gernhard S; Varghese A; Hoppe RT
Arch Dermatol; 2003 Jul; 139(7):857-66. PubMed ID: 12873880
[TBL] [Abstract][Full Text] [Related]
25. Should we be imaging lymph nodes at initial diagnosis of early-stage mycosis fungoides? Results from the PROspective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) international study.
Hodak E; Sherman S; Papadavid E; Bagot M; Querfeld C; Quaglino P; Prince HM; Ortiz-Romero PL; Stadler R; Knobler R; Guenova E; Estrach T; Patsatsi A; Leshem YA; Prague-Naveh H; Berti E; Alberti-Violetti S; Cowan R; Jonak C; Nikolaou V; Mitteldorf C; Akilov O; Geskin L; Matin R; Beylot-Barry M; Vakeva L; Sanches JA; Servitje O; Weatherhead S; Wobser M; Yoo J; Bayne M; Bates A; Dunnill G; Marschalko M; Buschots AM; Wehkamp U; Evison F; Hong E; Amitay-Laish I; Stranzenbach R; Vermeer M; Willemze R; Kempf W; Cerroni L; Whittaker S; Kim YH; Scarisbrick JJ;
Br J Dermatol; 2021 Mar; 184(3):524-531. PubMed ID: 32574377
[TBL] [Abstract][Full Text] [Related]
26. Prognostic factors in primary cutaneous lymphomas other than mycosis fungoides and the Sézary syndrome. The French Study Group on Cutaneous Lymphomas.
Grange F; Hedelin G; Joly P; Beylot-Barry M; D'Incan M; Delaunay M; Vaillant L; Avril MF; Bosq J; Wechsler J; Dalac S; Grosieux C; Franck N; Esteve E; Michel C; Bodemer C; Vergier B; Laroche L; Bagot M
Blood; 1999 Jun; 93(11):3637-42. PubMed ID: 10339469
[TBL] [Abstract][Full Text] [Related]
27. Lymph node classification systems in cutaneous T-cell lymphoma. Evidence for the utility of the Working Formulation of Non-Hodgkin's Lymphomas for Clinical Usage.
Vonderheid EC; Diamond LW; van Vloten WA; Scheffer E; Meijer CJ; Cashell AW; Hardman JM; Lai SM; Hermans J; Matthews MJ
Cancer; 1994 Jan; 73(1):207-18. PubMed ID: 8275427
[TBL] [Abstract][Full Text] [Related]
28. Revisiting the initial diagnosis and blood staging of mycosis fungoides and Sézary syndrome with the KIR3DL2 marker.
Roelens M; de Masson A; Ram-Wolff C; Maki G; Cayuela JM; Marie-Cardine A; Bensussan A; Toubert A; Bagot M; Moins-Teisserenc H
Br J Dermatol; 2020 Jun; 182(6):1415-1422. PubMed ID: 31487384
[TBL] [Abstract][Full Text] [Related]
29. Characteristics associated with significantly worse quality of life in mycosis fungoides/Sézary syndrome from the Prospective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) study.
Molloy K; Jonak C; Woei-A-Jin FJSH; Guenova E; Busschots AM; Bervoets A; Hauben E; Knobler R; Porkert S; Fassnacht C; Cowan R; Papadavid E; Beylot-Barry M; Berti E; Alberti Violetti S; Estrach T; Matin R; Akilov O; Vakeva L; Prince M; Bates A; Bayne M; Wachsmuch R; Wehkamp U; Marschalko M; Servitje O; Turner D; Weatherhead S; Wobser M; Sanches JA; McKay P; Klemke D; Peng C; Howles A; Yoo J; Evison F; Scarisbrick J
Br J Dermatol; 2020 Mar; 182(3):770-779. PubMed ID: 31049926
[TBL] [Abstract][Full Text] [Related]
30. TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC).
Kim YH; Willemze R; Pimpinelli N; Whittaker S; Olsen EA; Ranki A; Dummer R; Hoppe RT;
Blood; 2007 Jul; 110(2):479-84. PubMed ID: 17339420
[TBL] [Abstract][Full Text] [Related]
31. Prognosis of 100 Japanese patients with mycosis fungoides and Sézary syndrome.
Suzuki SY; Ito K; Ito M; Kawai K
J Dermatol Sci; 2010 Jan; 57(1):37-43. PubMed ID: 19931424
[TBL] [Abstract][Full Text] [Related]
32. European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome - Update 2017.
Trautinger F; Eder J; Assaf C; Bagot M; Cozzio A; Dummer R; Gniadecki R; Klemke CD; Ortiz-Romero PL; Papadavid E; Pimpinelli N; Quaglino P; Ranki A; Scarisbrick J; Stadler R; Väkevä L; Vermeer MH; Whittaker S; Willemze R; Knobler R
Eur J Cancer; 2017 May; 77():57-74. PubMed ID: 28365528
[TBL] [Abstract][Full Text] [Related]
33. Cytologic evaluation of lymphadenopathy associated with mycosis fungoides and Sezary syndrome: role of immunophenotypic and molecular ancillary studies.
Pai RK; Mullins FM; Kim YH; Kong CS
Cancer; 2008 Oct; 114(5):323-32. PubMed ID: 18798522
[TBL] [Abstract][Full Text] [Related]
34. Outcomes and prognostic factors in African American and black patients with mycosis fungoides/Sézary syndrome: Retrospective analysis of 157 patients from a referral cancer center.
Geller S; Lebowitz E; Pulitzer MP; Horwitz SM; Moskowitz AJ; Dusza S; Myskowski PL
J Am Acad Dermatol; 2020 Aug; 83(2):430-439. PubMed ID: 31499157
[TBL] [Abstract][Full Text] [Related]
35. Non-mycosis fungoides cutaneous lymphomas in a referral center in Taiwan: A retrospective case series and literature review.
Liu KL; Tsai WC; Lee CH
PLoS One; 2020; 15(1):e0228046. PubMed ID: 31978091
[TBL] [Abstract][Full Text] [Related]
36. Analysis of T-cell receptor gene rearrangement in lymph nodes of patients with mycosis fungoides. Prognostic implications.
Kern DE; Kidd PG; Moe R; Hanke D; Olerud JE
Arch Dermatol; 1998 Feb; 134(2):158-64. PubMed ID: 9487207
[TBL] [Abstract][Full Text] [Related]
37. Updated review on prognostic factors in mycosis fungoides and new skin lymphoma trials.
Farabi B; Seminario-Vidal L; Jamgochian M; Akay BN; Atak MF; Rao BK; Karagaiah P; Grabbe S; Goldust M
J Cosmet Dermatol; 2022 Jul; 21(7):2742-2748. PubMed ID: 34687485
[TBL] [Abstract][Full Text] [Related]
38. Clinical Presentation and Outcome Differences Between Black Patients and Patients of Other Races and Ethnicities With Mycosis Fungoides and Sézary Syndrome.
Allen PB; Goyal S; Niyogusaba T; O'Leary C; Ayers A; Tarabadkar ES; Khan MK; Lechowicz MJ
JAMA Dermatol; 2022 Nov; 158(11):1293-1299. PubMed ID: 36069854
[TBL] [Abstract][Full Text] [Related]
39. [Lymph node histopathologic aspects in cutaneous lymphomas of the mycosis fungoides or Sézary syndrome type. Retrospective study of 98 biopsies].
Wechsler J; Diebold J; Gerard-Marchant R
Ann Pathol; 1987; 7(2):122-9. PubMed ID: 3620027
[TBL] [Abstract][Full Text] [Related]
40. Image-guided lymph node core needle biopsy in mycosis fungoides/Sézary syndrome: Direct comparison to surgical excision.
Cury-Martins J; Netto SDDC; de Castro SCC; Siqueira SAC; Giannotti MA; Zerbini MCN; Pereira J; Culler H; Teixeira FJR; de Menezes MR; Sanches JA
J Dtsch Dermatol Ges; 2022 Jul; 20(7):1008-1010. PubMed ID: 35672256
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
